#antisenseoligonucleotide
LightNews LightNews
pagepress.bsky.social
| Efficacy and safety of #antisenseoligonucleotide therapies targeting APoC-III in patients with severe #hypertriglyceridemia: a meta-analysis of randomized controlled trials | doi.org/10.4081/mona... | #openaccess #academicsky #medsky |
February 23, 2026 at 1:04 PM
pharmaphorum.bsky.social
#GSK has announced that #Japan’s Ministry of Health, Labour and Welfare has approved Hibsago (#bepirovirsen), an #antisenseoligonucleotide, as a functional cure in #chronichepatitisB virus infection.

pharmaphorum.com/news/japan-f...
Japan first approval for GSK’s bepirovirsen for CHB
Japan has approved GSK's antisense oligonucleoide Hibsago (bepirovirsen) as a functional cure in chronic hepatitis B virus infection in adult patients
pharmaphorum.com
August 24, 2026 at 10:55 AM
4040rec.bsky.social
#Biogen #Dravetsyndrome #childhoodepilepsy #StokeTherapeutics #zorevunersen #EMPERORtrial #antisenseoligonucleotide #ASO #SCN1Agenemutation #EPNS #Developmentalencephalopathy #epilepticencephalopathy #Dravetsyndromepatients #SUDEP #paediatricneurology
pharmaphorum.com/news/case-bu...
Case builds for Biogen, Stoke's Dravet syndrome drug
Hopes have risen for a new treatment for severe childhood epilepsy Dravet syndrome, on the back of new data for Biogen and Stoke's zorevunersen
pharmaphorum.com
July 15, 2025 at 1:29 PM
jamaneurology.com
Among infants with genetic #Epilepsy, 16% had variants amenable to #AntisenseOligonucleotide therapies; most could be considered for precision treatment currently or at seizure onset.

ja.ma/4deV84L
Diagrams illustrate 'Assessment based on N=1 Collaborative VARIANT guidelines' and 'Assessment based on splice-switching framework,' showing exon skipping, knockdown, wild-type upregulation, and splice correction. Text includes: BRAT1@1, TNPO2@1, AIMP1@1.
May 10, 2026 at 2:00 PM
jamaneurology.com
Among infants with genetic #Epilepsy, 16% had variants amenable to #AntisenseOligonucleotide therapies; most could be considered for precision treatment currently or at seizure onset. ja.ma/3ODbwUz
Diagrams show 'Assessment based on N=1 Collaborative VARIANT guidelines' and 'Assessment based on splice-switching framework'. Examples include Exon skipping, Knockdown, Wild-type upregulation, and Splice correction, showing eligible variants such as text@1, text@2, text@3.
May 6, 2026 at 2:00 PM
gmj-georgia.bsky.social
Breakthrough in hepatitis B treatment: Phase 3 trial results for bepirovirsen antisense therapy published in NEJM. This novel approach targe…

#Antisenseoligonucleotide #Bepirovirsen #Functionalcure #HepatitisB #Phase3trial

#Antisenseoligonucleotide #Bepirovirsen #Functionalcure #HepatitisB #Pha…
New Hepatitis B Treatment Shows Promise in Trial
Breakthrough in hepatitis B treatment: Phase 3 trial results for bepirovirsen antisense therapy published in NEJM. This novel approach targe… #Antisenseoligonucleotide #Bepirovirsen #Functionalcure #HepatitisB #Phase3trial
news.gmj.ge
May 29, 2026 at 12:38 PM
gmj-georgia.bsky.social
Breakthrough in hepatitis B treatment: Phase 3 trial results for bepirovirsen antisense therapy published in NEJM. This novel approach targe…

#Antisenseoligonucleotide #Bepirovirsen #Functionalcure #HepatitisB #Phase3trial

#Antisenseoligonucleotide #Bepirovirsen #Functionalcure #HepatitisB #Pha…
New Hepatitis B Treatment Shows Promise in Trial
Breakthrough in hepatitis B treatment: Phase 3 trial results for bepirovirsen antisense therapy published in NEJM. This novel approach targe… #Antisenseoligonucleotide #Bepirovirsen #Functionalcure #HepatitisB #Phase3trial
news.gmj.ge
May 29, 2026 at 12:36 PM
gmj-georgia.bsky.social
Breakthrough in hepatitis B treatment: Phase 3 trial results for bepirovirsen antisense therapy published in NEJM. This novel approach targe…

#Antisenseoligonucleotide #Bepirovirsen #Functionalcure #HepatitisB #Phase3trial

#Antisenseoligonucleotide #Bepirovirsen #Functionalcure #HepatitisB #Pha…
New Hepatitis B Treatment Shows Promise in Trial
Breakthrough in hepatitis B treatment: Phase 3 trial results for bepirovirsen antisense therapy published in NEJM. This novel approach targe… #Antisenseoligonucleotide #Bepirovirsen #Functionalcure #HepatitisB #Phase3trial
news.gmj.ge
May 29, 2026 at 12:35 PM
gmj-georgia.bsky.social
Breakthrough in hepatitis B treatment: Phase 3 trial results for bepirovirsen antisense therapy published in NEJM. This novel approach targe…

#Antisenseoligonucleotide #Bepirovirsen #Functionalcure #HepatitisB #Phase3trial

#Antisenseoligonucleotide #Bepirovirsen #Functionalcure #HepatitisB #Pha…
New Hepatitis B Treatment Shows Promise in Trial
Breakthrough in hepatitis B treatment: Phase 3 trial results for bepirovirsen antisense therapy published in NEJM. This novel approach targe… #Antisenseoligonucleotide #Bepirovirsen #Functionalcure #HepatitisB #Phase3trial
news.gmj.ge
May 29, 2026 at 12:35 PM